Pfizer’s 6.7% Dividend Yield Reignites Safety Debate, but Management Points to Cash-Flow Plans and Post-2028 Visibility

Pfizer’s dividend yield near 6.7% has once again become a focal point for investors, according to recent market commentary that argued the payout’s headline size makes the risk of a cut look “scary,” especially relative to broad benchmarks and the typical pharma yield. The discussion stems from the simple math behind yield, annualized payments of $1.72 per share versus a share price in the mid-$20s around the time of the article.

Pfizer’s current regular quarterly dividend is $0.43 per share. The company disclosed that its board declared a $0.43 first-quarter 2026 dividend, and its dividend history also shows $0.43 for the most recent quarter reflected in mid-2026 trading. Because the dividend yield moves with the stock price, the same payment can look safer or riskier depending on how the market values Pfizer’s prospects in any given month.

Despite the yield, Pfizer is emphasizing that dividends remain part of its core capital allocation plan even as it faces the pharmaceutical industry’s recurring loss-of-exclusivity (LOE) cycle, when revenue declines after patents and marketing exclusivities expire. In prepared remarks for its Q1 2026 earnings call, management said improved visibility into cash flow after 2028 is a positive for longer-term capital allocation priorities, including “our ability to preserve and support the dividend.”

Management also used concrete Q1 cash-and-capital figures to frame the dividend debate. In the quarter, Pfizer said it invested $2.5 billion in internal research and development and returned $2.4 billion to shareholders via the quarterly dividend. It also reported first-quarter 2026 operating cash flow of $2.6 billion, with leverage ending the quarter at about 2.8x. Pfizer added that it expects leverage to remain around current levels, or slightly higher, through the LOE transition period.

On the same earnings materials, Pfizer pointed investors to a strategy it described as “Invest to Maximize Post-2028 Growth.” The slide messaging connects continued investment in the pipeline and commercial capabilities with a stated intent to maintain, and over time grow, the dividend as the company delevers and builds long-term value. The remarks also tied that confidence to legal and contractual developments aimed at improving the outlook for EPS and cash flow post-2028.

Recent commentary, however, argued that the dividend can look overextended on earnings-based measures in the near term. The analysis cited a payout ratio around 130% and suggested that cash coverage, when measured against cash dividends relative to cash flow, was closer to “touch over 100%.” It also suggested the dividend could be safer than the headline yield implies, while acknowledging that this is not a guarantee.

For context, Pfizer’s Q1 2026 results also reinforced how much near-term performance can be affected by the post-COVID transition and the timing of demand for legacy products, alongside growth in areas such as oncology and other newer franchises. In its Q1 earnings communication, Pfizer described $14.5 billion in first-quarter revenues and reiterated that it is reaffirming its 2026 guidance while continuing investments and shareholder returns.

The key uncertainty is what happens after the immediate LOE transition, since Pfizer’s published messaging in these materials stresses intentions and longer-term visibility rather than providing a specific, disclosed “dividend coverage” forecast for multiple years. Management said it expects leverage to stay around current levels through the transition, but it did not spell out a contingency plan for dividend capacity under a worse-than-expected cash-flow scenario in the near term. Investors are likely to watch whether Pfizer’s cash generation can sustain the dividend while it keeps funding its R&D pipeline and manages debt through 2026-2028.